Paper29324969
Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution.
Venkatesan S and 8 others. Ann Oncol, 2018. Cited by 128 papers, by iCite.
Cite this record
ConductScience Library. Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution. Papers, record 29324969. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29324969
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| APOBEC Deaminases | Major topic |
| Drug Resistance | Major topic |
| Mutagenesis | Major topic |
| Neoplasms | Major topic |
| Animals | |
| HIV | |
| HIV Infections | |
| Humans | |
| Immune Tolerance |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R21 CA206309 | NCI NIH HHS | United States | R21CA206309 | PubMed and NIH | NIH RePORTER |
| 24956 | Cancer Research UK | United Kingdom | PubMed | PubMed | |
| R37 AI064046 | NIAID NIH HHS | United States | R37AI064046 | PubMed and NIH | NIH RePORTER |
| 22246 | Cancer Research UK | United Kingdom | PubMed | PubMed | |
| FC001169 | Wellcome Trust | United Kingdom | PubMed | PubMed |
References89
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21460793 | APOBEC3A can activate the DNA damage response and cause cell-cycle arrest. | EMBO Rep | 2011 | https://conductscience.org/library/papers/21460793 | PubMed |
| 2 | 26375597 | Extremely High Mutation Rate of HIV-1 In Vivo. | PLoS Biol | 2015 | https://conductscience.org/library/papers/26375597 | PubMed |
| 3 | 28535155 | Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells. | Br J Cancer | 2017 | https://conductscience.org/library/papers/28535155 | PubMed |
| 4 | 21172829 | Analysis of reptilian APOBEC1 suggests that RNA editing may not be its ancestral function. | Mol Biol Evol | 2011 | https://conductscience.org/library/papers/21172829 | PubMed |
| 5 | 27321955 | Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. | Cancer Cell | 2016 | https://conductscience.org/library/papers/27321955 | PubMed |
| 6 | 26459911 | The eQTL-missense polymorphisms of APOBEC3H are associated with lung cancer risk in a Han Chinese population. | Sci Rep | 2015 | https://conductscience.org/library/papers/26459911 | PubMed |
| 7 | 20660203 | Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure. | J Virol | 2010 | https://conductscience.org/library/papers/20660203 | PubMed |
| 8 | 23852170 | An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. | Nat Genet | 2013 | https://conductscience.org/library/papers/23852170 | PubMed |
| 9 | 12167863 | Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. | Nature | 2002 | https://conductscience.org/library/papers/12167863 | PubMed |
| 10 | 24910434 | APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. | Cell Rep | 2014 | https://conductscience.org/library/papers/24910434 | PubMed |
| 11 | 19910370 | HIV-1 Vif binds to APOBEC3G mRNA and inhibits its translation. | Nucleic Acids Res | 2010 | https://conductscience.org/library/papers/19910370 | PubMed |
| 12 | 12809610 | DNA deamination mediates innate immunity to retroviral infection. | Cell | 2003 | https://conductscience.org/library/papers/12809610 | PubMed |
| 13 | 19479085 | Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. | PLoS One | 2009 | https://conductscience.org/library/papers/19479085 | PubMed |
| 14 | 28698210 | APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition. | Cancer Res | 2017 | https://conductscience.org/library/papers/28698210 | PubMed |
| 15 | 18832245 | Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18832245 | PubMed |
| 16 | 18846074 | Enhancing immunity to HIV through APOBEC. | Nat Biotechnol | 2008 | https://conductscience.org/library/papers/18846074 | PubMed |
| 17 | 27283319 | Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. | Sci Rep | 2016 | https://conductscience.org/library/papers/27283319 | PubMed |
| 18 | 28445112 | Tracking the Evolution of Non-Small-Cell Lung Cancer. | N Engl J Med | 2017 | https://conductscience.org/library/papers/28445112 | PubMed |
| 19 | 28431010 | Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy. | J Infect Dis | 2017 | https://conductscience.org/library/papers/28431010 | PubMed |
| 20 | 21270108 | Paradoxical relationship between chromosomal instability and survival outcome in cancer. | Cancer Res | 2011 | https://conductscience.org/library/papers/21270108 | PubMed |
Cited by98
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 128 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42640400 | Neuroendocrine Neoplasms of the Urinary Bladder: Integrating Molecular Advances into a Refined Classification System. | Endocr Pathol | 2026 | https://conductscience.org/library/papers/42640400 | PubMed |
| 42244370 | HIV-1 APOBEC-context Mutations Detected by Next-Generation Sequencing in Plasma: Implications for Drug Resistance Interpretation. | J Infect Dis | 2026 | https://conductscience.org/library/papers/42244370 | PubMed |
| 41651672 | Effects of thymidylate synthase inhibitors differ in genomic uracilation and mutagenic potential. | Life Sci Alliance | 2026 | https://conductscience.org/library/papers/41651672 | PubMed |
| 41554709 | Guardian ubiquitin E3 ligases target cancer-associated APOBEC3 deaminases for degradation to promote human genome integrity. | Nat Commun | 2026 | https://conductscience.org/library/papers/41554709 | PubMed |
| 41279821 | TyCHE enables time-resolved lineage tracing of heterogeneously-evolving populations. | bioRxiv | 2025 | https://conductscience.org/library/papers/41279821 | PubMed |
| 41065174 | Molecular and immune characteristics of neuroendocrine bladder carcinoma - Implications for diagnosis, prognosis, and therapy: A review. | Biomol Biomed | 2025 | https://conductscience.org/library/papers/41065174 | PubMed |
| 41044082 | Structural basis for sequence context-independent single-stranded DNA cytosine deamination by the bacterial toxin SsdA. | Nat Commun | 2025 | https://conductscience.org/library/papers/41044082 | PubMed |
| 41012606 | APOBEC3B Promotes SARS-CoV-2 Through Activation of PKR/eIF2⍺ and AMPD2 Dysregulation. | Viruses | 2025 | https://conductscience.org/library/papers/41012606 | PubMed |
| 40813533 | SARS-CoV-2 infection heightens the risk of developing HPV-related carcinoma in situ and cancer. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40813533 | PubMed |
| 40713522 | Comprehensive Insights into APOBEC Mutations in Thyroid Cancer: Prognostic and Therapeutic Discoveries. | Biol Proced Online | 2025 | https://conductscience.org/library/papers/40713522 | PubMed |
| 40516913 | Deciphering molecular pathways in urological cancers: A gateway to precision therapeutics. | J Adv Res | 2026 | https://conductscience.org/library/papers/40516913 | PubMed |
| 40156866 | Next generation APOBEC3 inhibitors: optimally designed for potency and nuclease stability. | Nucleic Acids Res | 2025 | https://conductscience.org/library/papers/40156866 | PubMed |
| 40004025 | APOBEC3-Related Editing and Non-Editing Determinants of HIV-1 and HTLV-1 Restriction. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40004025 | PubMed |
| 39322638 | Characterisation of APOBEC3B-Mediated RNA editing in breast cancer cells reveals regulatory roles of NEAT1 and MALAT1 lncRNAs. | Oncogene | 2024 | https://conductscience.org/library/papers/39322638 | PubMed |
| 39046884 | Deciphering lung adenocarcinoma prognosis and immunotherapy response through an AI-driven stemness-related gene signature. | J Cell Mol Med | 2024 | https://conductscience.org/library/papers/39046884 | PubMed |
| 38868014 | APOBEC3-related mutations in the spike protein-encoding region facilitate SARS-CoV-2 evolution. | Heliyon | 2024 | https://conductscience.org/library/papers/38868014 | PubMed |
| 38774272 | Synthesis of 1,4-azaphosphinine nucleosides and evaluation as inhibitors of human cytidine deaminase and APOBEC3A. | Beilstein J Org Chem | 2024 | https://conductscience.org/library/papers/38774272 | PubMed |
| 38499553 | Distinguishing preferences of human APOBEC3A and APOBEC3B for cytosines in hairpin loops, and reflection of these preferences in APOBEC-signature cancer genome mutations. | Nat Commun | 2024 | https://conductscience.org/library/papers/38499553 | PubMed |
| 38318650 | Antiviral factors and their counteraction by HIV-1: many uncovered and more to be discovered. | J Mol Cell Biol | 2024 | https://conductscience.org/library/papers/38318650 | PubMed |
| 38033156 | Mutational impact of APOBEC3A and APOBEC3B in a human cell line and comparisons to breast cancer. | PLoS Genet | 2023 | https://conductscience.org/library/papers/38033156 | PubMed |
Genes26
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29324969
GET https://conductscience.org/api/papers/v1/29324969/references?page=2